トラスツズマブとペルスツズマブの併用で高い治療効果

Pertuzumab is a antibody drug to HER2 receptor and is expected as a new medicine to treat the HER2 positive breast cancer.
At present, HER2 positive breast cancer treatment is used Trastuzumab (Herceptin) and Lapatinib (Tykerb).

However, it is known that some resistants exist in these patients and we need the other options to them.
Pertuzumab recognize other epitope of HER2 compared to Trastuzumab, so this is thought to be available with Trastuzumab.
This might be a new option to treat HER2 positive breast cancer.

This news said this possibility.

　HER2陽性乳癌の術前補助療法としてトラスツズマブ、Pertuzumabは標準化学療法と併用しても循環器への影響、全体の安全性は許容範囲で、高い効果を示すことが明らかとなった。オープンラベル多施設無作為化フェーズ2試験であるTRYPHAENA試験の結果示されたもの。3月21日から24日にオーストリアウィーンで開催されている第8回European Breast Cancer Conference（EBCC）で、ドイツNationales Centrum fur TumorerkrankungenのA.Schneeweiss氏によって発表された。

However, Trastuzumab is very expensive drug and probably Pertuzumab will be the same too.
If we would utilize Pertuzumab, the cost of these combination therapy would be incredibly expensive.

I hope to utilize more affordable therapy or I want to know how to stratify the sensitive or not.